IMVIONIX, a privately held biotechnology company dedicated to advancing the delivery of retinal therapies, announced that it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in Canada and the United States from Novartis. This acquisition marks the official commercial launch of IMVIONIX and represents the company’s first strategic transaction in its mission to improve vision by advancing the reach of retinal therapies where unmet needs for patients and physicians persist.
“We founded IMVIONIX because we believe there are proven retinal therapies where physicians and patients can further benefit from the focus and reach of a dedicated retina company,” said Rick Eiswirth, Founder and Chief Executive Officer of IMVIONIX. “Building on the strong foundation already established for BEOVU, this acquisition exemplifies the type of opportunity IMVIONIX was built to pursue.” IMVIONIX believes that an organization with deep relationships in the retina community is best positioned to expand the reach of such therapies and bring them to the physicians and patients who may potentially benefit most. “We are excited to bring our focused commercial expertise to bear on behalf of the retina community,” Eiswirth continued.
BEOVU Indications and Leadership Background
BEOVU is approved in both Canada and the United States for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), two leading causes of irreversible vision loss. Under the terms of the agreement, IMVIONIX will become the marketing authorization holder for BEOVU in Canada and the United States. Financial terms of the transaction were not disclosed.
IMVIONIX was founded in 2025 by the former executive management team of Alimera Sciences, Inc. — Rick Eiswirth, Jason Werner, Todd Wood, and Elliot Maltz — in collaboration with Caligan Partners LP and Velan Capital. The founding team brings a combined 60 years of expertise in ophthalmology.
“The acquisition of BEOVU marks an important first step in building IMVIONIX into a company that focuses on serving retina specialists and their patients,” Eiswirth added. “BEOVU has proven efficacy in two significant retinal conditions, and we believe it is well positioned to deliver additional meaningful value to the retina community. This acquisition reflects our core mandate — identifying therapies that align with our retina focused investment and commercialization platform. Our team has a proven track record of bringing ophthalmic therapies to market and we are well capitalized to execute on our mission.”
